Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Clinical Data, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pulmonary arterial hypertension (PAH) to PRX-8066, the Company's selective serotonin 2B (5-HT2B) receptor antagonist.

1 Nov 2010

Oncimmune to present benefits of EarlyCDT-Lung cancer test at ACCP annual meeting

Oncimmune® LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in the risk assessment and early detection of lung cancer, today announced that two oral presentations and five poster presentations during this week's American College of Chest Physicians' (ACCP) annual meeting in Vancouver will collectively highlight the clinical and economic benefits of EarlyCDT-Lung.

1 Nov 2010

Research on brain circuit activity may pave way to find biomarker for PTSD

University of Minnesota Medical School and Minneapolis Veterans Affair Medical Center researchers have discovered a correlation between increased circuit activity in the right side of the brain and the debilitating, involuntary flashbacks triggered by post traumatic stress disorder (PTSD).

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

Max Planck Innovation licenses new software for metabolite analysis

Max Planck Innovation licenses analysis-technology for metabolites . Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research.

28 Oct 2010

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer, were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

28 Oct 2010

TU/e researchers mimic process of bone formation in laboratory

Researchers at Eindhoven University of Technology (TU/e) have for the first time succeeded in mimicking the process of bone formation in the laboratory, and in visualizing the process in great detail. The results will be published in the December edition of the scientific journal Nature Materials.

28 Oct 2010

IBI receives U.S. patent for novel blood protein biomarkers

Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

28 Oct 2010

PCT technology improves DNA extraction method in forensic evidentiary samples

Pressure BioSciences, Inc. today announced that two scientific presentations at the 21st International Symposium on Human Identification have provided further evidence that pressure cycling technology offers an improved method for the extraction of DNA in the analysis of forensic evidentiary samples.

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

PPD and VirtualScopics partner to provide medical imaging services

PPD, Inc. and VirtualScopics, Inc. today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

26 Oct 2010

Study on gene variant associated with narcolepsy

Ever wonder why some people breeze along on four hours of sleep when others can barely function? It may be in our genes, according to new research and an accompanying editorial published in the October 26, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

26 Oct 2010

Daily dose of whole body vibration reduces bone density loss

A daily dose of whole body vibration may help reduce the usual bone density loss that occurs with age, Medical College of Georgia researchers report.

25 Oct 2010

Targeting c-Met protein may be effective for patients with metastatic liver cancer

A more personalized treatment for people with a type of metastatic liver cancer hepatocellular carcinoma may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers.

25 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Atherotech to present VAP Cholesterol Test at OMED 2010

Atherotech Diagnostics Lab will showcase its VAP Cholesterol Test in booth 324 at the American Osteopathic Association's 115th Annual Osteopathic Medical Conference & Exposition (OMED 2010). The gathering of DOs, residents, interns, students, researchers and health care professionals will be held October 24-28 at Moscone Convention Center in San Francisco.

22 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010